HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suzanne D Borgel Selected Research

Neoplasms (Cancer)

5/2014Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.
12/2011Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts.
7/2011ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.
8/2009Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
7/2009Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
4/2007Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
10/2004Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
6/2003"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Suzanne D Borgel Research Topics

Disease

8Neoplasms (Cancer)
05/2014 - 06/2003
4Hypoxia (Hypoxemia)
08/2009 - 06/2003
2Neoplasm Metastasis (Metastasis)
07/2011 - 04/2007
1Alveolar Soft Part Sarcoma
08/2009
1Glioblastoma (Glioblastoma Multiforme)
10/2004

Drug/Important Bio-Agent (IBA)

3Proteins (Proteins, Gene)FDA Link
07/2011 - 10/2004
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2011 - 06/2003
3Topotecan (Hycamtin)FDA LinkGeneric
08/2009 - 10/2004
2Pharmaceutical PreparationsIBA
12/2011 - 06/2003
2Bevacizumab (Avastin)FDA Link
08/2009 - 07/2009
2AntibodiesIBA
08/2009 - 06/2003
1adavosertibIBA
05/2014
1tyrosine receptor (receptor, tyrosine)IBA
05/2014
1Complementary DNA (cDNA)IBA
05/2014
1Phosphotransferases (Kinase)IBA
05/2014
1AgarIBA
07/2011
1Transcription Factors (Transcription Factor)IBA
07/2011
1fluorescein isothiocyanate dextranIBA
08/2009
1AmylasesFDA Link
08/2009
1Periodic AcidIBA
08/2009
1CD34 Antigens (CD34 Antigen)IBA
08/2009
1SuspensionsIBA
04/2007
1Paclitaxel (Taxol)FDA LinkGeneric
04/2007
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/2007
1PoisonsIBA
10/2004
1Type I DNA Topoisomerases (Topoisomerase I)IBA
10/2004
1A-Form DNA (A-DNA)IBA
10/2004
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
06/2003
1RazoxaneIBA
06/2003
1O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA
06/2003

Therapy/Procedure

4Therapeutics
05/2014 - 06/2003
1Transplantation
04/2007